TY - JOUR
TI - Assessment of the European classification criteria for Sjogren's
syndrome in a series of clinically defined cases: Results of a
prospective multicentre study
AU - Vitali, C
AU - Bombardieri, S
AU - Moutsopoulos, HM
AU - Coll, J
AU - Gerli,
AU - R
AU - Hatron, PY
AU - Kater, L
AU - Konttinen, YT
AU - Manthorpe, R and
AU - Meyer, O
AU - Mosca, M
AU - Ostuni, P
AU - Pellerito, RA
AU - Pennec, Y and
AU - Porter, SR
AU - Richards, A
AU - Sauvezie, B
AU - Schiodt, M
AU - Sciuto, M
AU - and Shoenfeld, Y
AU - Skopouli, FN
AU - Smolen, JS
AU - Soromenho, F and
AU - Tishler, M
AU - Tomsic, M
AU - vandeMerwe, JPV
AU - Yeoman, CM and
AU - Wattiaux, MJ
AU - Hitzelhammer, J
AU - Petera, P
AU - Hietanen, J and
AU - Malmstrom, M
AU - Youniou, P
AU - Grossin, M
AU - Kahn, MF
AU - Ehrenfeld, M
AU - and Ianniello, A
AU - Sfriso, P
AU - Ercolani, R
AU - Muscat, C and
AU - DeGiovanni, R
AU - Rizzi, L
AU - vandenHoogen, FHJ
AU - Hoodkaas, H and
AU - Kruize, AA
AU - Alves, J
AU - Presetnik, M
AU - Rozman, B
AU - Axell, T and
AU - Larsson, A
AU - Tabety, H
AU - Maddison, PJ
AU - Mutlu, S
AU - Scully, C and
AU - Franklin, CD
AU - Nelson, M
JO - Annals of the Rheumatic Diseases
PY - 1996
VL - 55
TODO - 2
SP - 116-121
PB - BMJ Publishing Group
SN - 0003-4967, 1468-2060
TODO - 10.1136/ard.55.2.116
TODO - null
TODO - Objective-To assess the recently proposed preliminary criteria for the
classification of Sjogren’s syndrome (SS) in a multicentre European
study of a new series of clinically defined cases.
Methods-The criteria included six items: I = ocular symptoms; II = oral
symptoms; III = evidence of keratoconjunctivitis sicca; IV = focal
sialoadenitis by minor salivary gland biopsy; V = instrumental evidence
of salivary gland involvement; VI = presence of autoantibodies. Each
centre was asked to provide five patients with primary SS, dive with
secondary SS, five with connective tissue diseases (CTD) but without SS,
and five controls (patients with ocular or oral features that may
simulate SS). The preliminary six item classification criteria set was
applied to both the SS patients and the non-SS controls, and the
performance of the criteria in terms of sensitivity and specificity was
tested.
Results-The criteria set was tested on a total of 278 cases (157 SS
patients and 121 non-SS controls) collected from 16 centres in 10
countries. At least four of the six items in the criteria set (Limiting
item VI to the presence of Ro(SS-A) or La(SS-B) antibodies) were present
in 79 of 81 patients initially classified as having primary SS
(sensitivity 97.5%), but in only seven of 121 non-SS controls
(specificity 94.2%). When the presence of item I or II plus any two of
items III-V of the criteria set was considered as indicative of
secondary SS, 97.3% (71 of 73) of the patients initially defined as
having this disorder and 91.8% (45 of 49) of the control patients with
CTD without SS were correctly classified.
Conclusion-This prospective study confirmed the high validity and
reliability of the classification criteria for SS recently proposed by
the European Community Study Group.
ER -